Replies to post #211849 on Biotech Values

[DewDiligence]

FDA approves ALXN’s Soliris for gMG:

http://www.businesswire.com/news/home/20171023006539/en/

Alexion Pharmaceuticals…announced today that the U.S. Food and Drug Administration has approved Soliris (eculizumab) as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive. In the Phase 3 REGAIN study and its ongoing open-label extension study, Soliris demonstrated treatment benefits for patients with anti-AchR antibody-positive gMG who had previously failed immunosuppressive treatment and continued to suffer from significant unresolved disease symptoms…

Today was the PDUFA date.